GT Biopharma, Inc., an immuno-oncology biotechnology company focused on treatments based on its NK-engager and Bispecific Antibody Drug Conjugate platforms, has completed a restructuring of its management team. Anthony J Cataldo has been named chairman and chief executive officer. Mr. Cataldo founded and served as chairman and chief executive officer at Iovance Biotherapeutics, Inc. with assets purchased from the National Cancer Institute (NCI). Iovance has a market capitalization more than $...